What is Thymosin α1?
Thymosin α1 is a protein in humans encoded by the PTMA gene, which is a peptide fragment derived from prothymosin alpha, exhibits a variety of immunoregulating properties. It is approved for the treatment of Hepatitis B and C, in 35 under-developed or developing countries.
Global Thymosin α1 Market Outlook
The rising burden and incidence of HAV and HBV are driving the growth of Thymosin α1 market. In 2015, 257 million people were diagnosed with chronic HBV infection, and 71 million people with chronic HCV infection, this figure to reach a peak by 2030. Eastern Mediterranean Region and the European Region are reported with the highest prevalence of HCV.
Ongoing trials and research for new applications or treatments to propel the growth of the market. Clinical trials entail that thymosin α1 can be useful in cystic fibrosis, peritonitis, acute cytomegalovirus infection, TB, severe acute respiratory syndrome, and lung infections in critically ill patients., septic shock and acute respiratory distress syndrome. It has been studied for probable use in treating cancer during chemotherapy. Thymosin α1 has been given to subjects with lung, gastric, or breast cancer in China. It was given for evaluation during one of two cycles of chemotherapy and QOL, treatment with Thymosin α1 provided a significant improvement in all measures of QOL as well as a lowered occurrence of infections during chemotherapy and increased immune parameters. Lack of awareness among the rural population about hepatitis and its treatment is hindering the growth of the market.
Global Thymosin α1 Market Competitive Landscape
The "Global Thymosin α1 Market" study report will provide a valuable insight with an emphasis on global market including some of the major players such as Suzhou Tianma Pharma Group Tianji Bio-pharmaceutical, Hainan Zhonghe Pharmaceutical, SciClone Pharmaceuticals, Abbiotec, Shanghai Soho-Yiming Pharmaceuticals, Hybio Pharmaceutical and Hainan Shuangcheng Pharmaceuticals. Our market analysis also entails a section solely dedicated for such major players wherein our analysts provide an insight to the financial statements of all the major players, along with its product benchmarking and SWOT analysis.
Customization of the Report
• In case of any queries or customization requirements please connect with our sales team, who will ensure that your requirements are met.
1. INTRODUCTION OF GLOBAL THYMOSIN Α1 MARKET
1.1. Overview of the Market
1.2. Scope of Report
1.3. Assumptions
2. EXECUTIVE SUMMARY
3. RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH
3.1. Data Mining
3.2. Validation
3.3. Primary Interviews
3.4. List of Data Sources
4. GLOBAL THYMOSIN Α1 MARKET OUTLOOK
4.1. Overview
4.2. Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.3. Porters Five Force Model
4.4. Value Chain Analysis
5. GLOBAL THYMOSIN Α1 MARKET, BY TYPE
5.1. Overview
5.2. Freeze-dried Powder
5.3. Injection
6. GLOBAL THYMOSIN Α1 MARKET, BY DISTRIBUTION CHANNEL
6.1. Overview
6.2. Hospital Pharmacies
6.3. Retail Pharmacies
6.4. Online Pharmacies
7. GLOBAL THYMOSIN Α1 MARKET, BY GEOGRAPHY
7.1. Overview
7.2. North America
7.2.1. U.S.
7.2.2. Canada
7.2.3. Mexico
7.3. Europe
7.3.1. Germany
7.3.2. U.K.
7.3.3. France
7.3.4. Rest of Europe
7.4. Asia Pacific
7.4.1. China
7.4.2. Japan
7.4.3. India
7.4.4. Rest of Asia Pacific
7.5. Rest of the World
7.5.1. Latin America
7.5.2. Middle East & Africa
8. GLOBAL THYMOSIN Α1 MARKET COMPETITIVE LANDSCAPE
8.1. Overview
8.2. Company Market Ranking
8.3. Key Development Strategies
9. COMPANY PROFILES
9.1. Suzhou Tianma Pharma Group Tianji Bio-pharmaceutical
10.1.1 Overview
10.1.2 Financial Performance
10.1.3 Product Outlook
10.1.4 Key Developments
9.2. Abbiotec
9.2.1. Overview
9.2.2. Financial Performance
9.2.3. Product Outlook
9.2.4. Key Developments
9.3. Shanghai Soho-Yiming Pharmaceuticals
9.3.1. Overview
9.3.2. Financial Performance
9.3.3. Product Outlook
9.3.4. Key Developments
9.4. Hybio Pharmaceutical
9.4.1. Overview
9.4.2. Financial Performance
9.4.3. Product Outlook
9.4.4. Key Developments
9.5. Hainan Shuangcheng Pharmaceuticals
9.5.1. Overview
9.5.2. Financial Performance
9.5.3. Product Outlook
9.5.4. Key Developments
10. Appendix
10.1. Related Reports
| Price : US$ 3500 | Date : Sep 2023 |
| Category : Healthcare and Pharmaceuticals | Pages : 155 |
| Price : US$ 3500 | Date : Sep 2023 |
| Category : Healthcare and Pharmaceuticals | Pages : 147 |
| Price : US$ 3500 | Date : Jul 2023 |
| Category : Healthcare and Pharmaceuticals | Pages : 231 |
| Price : US$ 3500 | Date : Oct 2022 |
| Category : Healthcare and Pharmaceuticals | Pages : 157 |
| Price : US$ 3500 | Date : Sep 2022 |
| Category : Healthcare and Pharmaceuticals | Pages : 161 |
We will be happy to help you find what you need. Please call us or write to us:
Want us to send you latest updates of the current trends, insights, and more, signup to our newsletter (for alerts, special offers, and discounts).
This website is secured Origin CA certificate on the server, Comodo, Firewall and Verified Sitelock Malware Protection
Request Sample 
Request Discount 
Inquire Before Buy
